Production of recombinant botulism antigens: A review of expression systems

Anaerobe

Volumn 28, Issue , 2014, Pages 130-136

  Moreira, G M S G ^a   Cunha, C E P ^a   Salvarani, F M ^b   Goncalves L A ^b   Pires, P S ^b   Conceicao F R ^a   Lobato, F C F ^b  

^a FEDERAL UNIVERSITY OF PELOTAS   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Botulinum neurotoxin; Clostridium botulinum; Escherichia coli; Pichia pastoris; Recombinant toxins

Indexed keywords

ADENOVIRUS VECTOR; ALCOHOL OXIDASE; BOTULINUM TOXIN; ESCHERICHIA COLI PROTEIN; RECOMBINANT ANTIGEN; RECOMBINANT BOTULISM ANTIGEN; RECOMBINANT HOLOTOXIN; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; RECOMBINANT PROTEIN;

ADAPTIVE IMMUNITY; AMINO TERMINAL SEQUENCE; ANAEROBIC FERMENTATION; ANTIGEN PRESENTATION; BACTERIUM TRANSFORMATION; BIOMASS; BIOSAFETY; BOTULISM; CARBOXY TERMINAL SEQUENCE; DRUG POTENCY; DRUG PURIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; GLYCOSYLATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; INCUBATION TIME; INFECTION PREVENTION; INTOXICATION; NONHUMAN; PICHIA PASTORIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; TEMPERATURE; VACCINATION; VACCINE PRODUCTION; ANIMAL; CLOSTRIDIUM BOTULINUM; GENE EXPRESSION; GENE VECTOR; GENETICS; IMMUNOLOGY; VETERINARY;

ANIMALS; ANTIGENS, BACTERIAL; BOTULINUM TOXINS; BOTULISM; CLOSTRIDIUM BOTULINUM; GENE EXPRESSION; GENETIC VECTORS; HUMANS; RECOMBINANT PROTEINS;

EID: 84903128827     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2014.06.003     Document Type: Review

References (90)

1. Krüger M., Skau M., Shehata A.A., Schrödl W. Efficacy of Clostridium botulinum types C and D toxoid vaccination in Danish cows. Anaerobe 2013, 23:97-101.
2. Chen C., Wang S., Wang H., Mao X., Zhang T., Ji G., et al. Potent neutralization of botulinum neurotoxin/B by synergistic action of antibodies recognizing protein and ganglioside receptor binding domain. PLoS One 2012, 7:e43845.
3. Dover N., Barash J.R., Hill K.K., Xie G., Arnon S.S. Molecular characterization of a novel botulinum neurotoxin type H gene. JInfect Dis 2014, 209:192-202.
4. Smith L.D.S. Botulism: the organism, its toxins, the disease 1977.
5. Suen J.C., Hatheway C.L., Steigerwalt A.G., Brenner D.J. Clostridiurn argentinense sp. nov.[U+202F]: a genetically homogeneous group composed of all strains of Clostridium botulinum toxin type G and some nontoxigenic strains previously identified as clostridium subterminale or clostridium hastiforme. Int J Syst Evol Microbiol 1988, 38:375-381.
6. McCroskey L.M., Hatheway C.L., Fenicia L., Pasolini B., Aureli P. Characterization of an organism that produces type E botulinal toxin but which resembles Clostridium butyricum from the feces of an infant with type E botulism. JClin Microbiol 1986, 23:201-202.
7. Franciosa G., Ferreira J.L., Hatheway C.L. Detection of type A, B, and E botulism neurotoxin genes in Clostridium botulinum and other Clostridium species by PCR: evidence of unexpressed type B toxin genes in type A toxigenic organisms. JClin Microbiol 1994, 32:1911-1917.
8. Schiavo G., Matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 2000, 80:717-766.
9. Lee K., Gu S., Jin L., Le T.T.N., Cheng L.W., Strotmeier J., et al. Structure of a bimodular botulinum neurotoxin complex provides insights into its oral toxicity. PLoS Pathog 2013, 9:e1003690.
10. Scott A.B., Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 1988, 3:333-335.
11. Connan C., Denève C., Mazuet C., Popoff M.R. Regulation of toxin synthesis in Clostridium botulinum and Clostridium tetani. Toxicon 2013, 75:90-100.
12. Poulain B., Lonchamp E., Jover E., Popoff M.R., Molgó J. Mechanisms of action of botulinum toxins and neurotoxins. Ann Dermatol Venereol 2009, 136(Suppl):S73-s76.
13. Brüggemann H. Genomics of clostridial pathogens: implication of extrachromosomal elements in pathogenicity. Curr Opin Microbiol 2005, 8:601-605.
14. Dolly J.O., Lawrence G.W., Meng J., Wang J., Ovsepian S.V. Neuro-exocytosis: botulinum toxins as inhibitory probes and versatile therapeutics. Curr Opin Pharmacol 2009, 9:326-335.
15. Verderio C., Rossetto O., Grumelli C., Frassoni C., Montecucco C., Matteoli M. Entering neurons: botulinum toxins and synaptic vesicle recycling. EMBO Rep 2006, 7:995-999.
16. Ravichandran E., Al-Saleem F.H., Ancharski D.M., Elias M.D., Singh A.K., Shamim M., et al. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun 2007, 75:3043-3054.
17. Aoki K.R., Smith L.A., Atassi M.Z. Mode of action of botulinum neurotoxins: current vaccination strategies and molecular immune recognition. Crit Rev Immunol 2010, 30:167-187.
18. Galey F.D. Botulism in the horse. Vet Clin North Am Equine Pract 2001, 17:579-588.
19. Yeruham I., Elad D., Avidar Y., Grinberg K., Tiomkin D., Monbaz A. Outbreak of botulism type B in a dairy cattle herd: clinical and epidemiological aspects. Vet Rec 2003, 153:270-272.
20. Hartley H.M., Clarke H.J., Graham D.A., Ball H.J., Malone F.E., Beggs N.W.R., et al. Detection of Clostridium botulinum type A toxin in a cow in Northern Ireland. Vet Rec 2009, 165:544.
21. Van der Lugt J.J., De Wet S.C., Bastianello S.S., Kellerman T.S., Van Jaarsveld L.P. Two outbreaks of type C and type D botulism in sheep and goats in south Africa. JS Afr Vet Assoc 1995, 66:77-82.
22. Bruchim Y., Steinman A., Markovitz M., Baneth G., Elad D., Shpigel N.Y. Toxicological, bacteriological and serological diagnosis of botulism in a dog. Vet Rec 2006, 158:768-769.
23. Skarin H., Lindberg A., Blomqvist G., Aspán A., Båverud V. Molecular characterization and comparison of Clostridium botulinum type C avian strains. Avian Pathol 2010, 39:511-518.
24. Rodloff A.C., Krüger M. Chronic Clostridium botulinum infections in farmers. Anaerobe 2012, 18:226-228.
25. Lobato F.C.F., Salvarani F.M., Gonçalves L.A., Pires P.S., Silva R.O.S., Alves G.G., et al. Clostridioses dos animais de produção. Veterinária e Zootec 2013, 20:29-48.
26. Döbereiner J., Tokarnia C.H., Langenegger J., Dutra I.S. Epizootic botulism of cattle in Brazil. Dtsch Tierarztl Wochenschr 1992, 99:188-190.
27. Dutra I.S., Döbereiner J., Rosa I.V., Souza L.A.A., Nonato M. Surtos de botulismo em bovinos no Brasil associados à ingestão de água contaminada. Pesqui Veterinária Bras 2001, 21:43-48.
28. Anniballi F., Fiore A., Löfström C., Skarin H., Auricchio B., Woudstra C., et al. Management of animal botulism outbreaks: from clinical suspicion to practical countermeasures to prevent or minimize outbreaks. Biosecur Bioterror 2013, 11(Suppl 1):S191-S199.
29. Baldassi L., Hipolito M., Portugal M.A., Calil E.M., Moulin A.A., Pires D.C. Bovine botulism: laboratory confirmation of clinical diagnosis in 1986-1989. Rev Saúde Pública 1991, 25:371-374.
30. Lobato F.C.F., Salvarani F.M., Assis R.A. Clostridioses dos pequenos ruminantes. Rev Port Ciências Veterinárias 2007, 102:23-34.
31. Myllykoski J., Lindström M., Keto-Timonen R., Söderholm H., Jakala J., Kallio H., et al. Type C bovine botulism outbreak due to carcass contaminated non-acidified silage. Epidemiol Infect 2009, 137:284-293.
32. Kelch W.J., Kerr L.A., Pringle J.K., Rohrbach B.W., Whitlock R.H. Fatal Clostridium botulinum toxicosis in eleven Holstein cattle fed round bale barley haylage. JVet Diagn Invest 2000, 12:453-455.
33. Lobato F.C.F., Melo M.A., Silva W., Diniz J.M. Botulismo causado pelo Clostridium botulinum tipo B. Arq Bras Med Veterinária e Zootec 1988, 40:445-446.
34. Steinman A., Chaffer M., Elad D., Shpigel N.Y. Quantitative analysis of levels of serum immunoglobulin G against botulinum neurotoxin type D and association with protection in natural outbreaks of cattle botulism. Clin Vaccine Immunol 2006, 13:862-868.
35. Gessler F. Anew scaleable method for the purification of botulinum neurotoxin type E. JBiotechnol 2005, 119:204-211.
36. Webb R.P., Smith L.A. What next for botulism vaccine development?. Expert Rev Vaccines 2013, 12:481-492.
37. Ebrahimi F., Rasaee M.J., Mousavi S.L., Babaeipour V. Production and characterization of a recombinant chimeric antigen consisting botulinum neurotoxin serotypes A, B and E binding subdomains. JToxicol Sci 2010, 35:9-19.
38. Clayton M.A., Clayton J.M., Brown D.R., Middlebrook J.L. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect Immun 1995, 63:2738-2742.
39. Arimitsu H., Lee J., Sakaguchi Y., Hayakawa Y., Hayashi M., Nakaura M., et al. Vaccination with recombinant whole heavy chain fragments of clostridium botulinum type C and D neurotoxins. Clin Diagn Lab Immunol 2004, 11:496-502.
40. Stahl C., Unger L., Mazuet C., Popoff M.R., Straub R., Frey J. Immune response of horses to vaccination with the recombinant Hc domain of botulinum neurotoxin types C and D. Vaccine 2009, 27:5561-5566.
41. Cunha C.E.P., Moreira G.M.S.G., Salvarani F.M., Neves M.S., Lobato F.C.F., Dellagostin O.A., et al. Vaccination of cattle with a recombinant bivalent toxoid against botulism serotypes C and D. Vaccine 2014, 32:214-216.
42. Boles J., West M., Montgomery V., Tammariello R., Pitt M.L.M., Gibbs P., et al. Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey. Toxicon 2006, 47:877-884.
43. Huang C.-J., Lin H., Yang X. Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements. JInd Microbiol Biotechnol 2012, 39:383-399.
44. Smith L.A. Development of recombinant vaccines for botulinum neurotoxin. Toxicon 1998, 36:1539-1548.
45. Smith L.A. Botulism and vaccines for its prevention. Vaccine 2009, 27:D33-D39.
46. Graumann K., Premstaller A. Manufacturing of recombinant therapeutic proteins in microbial systems. Biotechnol J 2006, 1:164-186.
47. Gao Y.-L., Gao S., Kang L., Nie C., Wang J.-L. Expression of Hc fragment from Clostridium botulinum neurotoxin serotype B in Escherichia coli and its use as a good immunogen. Hum Vaccin 2010, 6:462-466.
48. Jain S. Effect of adjuvants on antibody titer of synthetic recombinant light chain of botulinum neurotoxin type B and its diagnostic potential for botulism. JMicrobiol Biotechnol 2011, 21:719-727.
49. Kiyatkin N., Maksymowych A.B., Simpson L.L. Induction of an immune response by oral administration of recombinant botulinum toxin. Infect Immun 1997, 65:4586-4591.
50. Esposito D., Chatterjee D.K. Enhancement of soluble protein expression through the use of fusion tags. Curr Opin Biotechnol 2006, 17:353-358.
51. Lee J.-C., Hwang H.-J., Sakaguchi Y., Yamamoto Y., Arimitsu H., Tsuji T., et al. Cterminal half fragment (50 kDa) of heavy chain components of Clostridium botulinum type C and D neurotoxins can be used as an effective vaccine. Microbiol Immunol 2007, 51:445-455.
52. Yu Y.-Z., Li N., Wang R.-L., Zhu H.-Q., Wang S., Yu W.-Y., et al. Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine. Clin Vaccine Immunol 2008, 15:1819-1823.
53. Yu Y.-Z., Li N., Zhu H.-Q., Wang R.-L., Du Y., Wang S., et al. The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate. Vaccine 2009, 27:2816-2822.
54. Yu Y.-Z., Zhang S.-M., Ma Y., Zhu H.-Q., Wang W.-B., Du Y., et al. Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F. Clin Immunol 2010, 137:271-280.
55. Holley J.L., Elmore M., Mauchline M., Minton N., Titball R.W. Cloning, expression and evaluation of a recombinant sub-unit vaccine against Clostridium botulinum type F toxin. Vaccine 2000, 15:288-297.
56. Yari K., Fatemi S.S.-A., Tavallaei M. High level expression of recombinant BoNT/A-Hc by high cell density cultivation of Escherichia coli. Bioprocess Biosyst Eng 2012, 35:407-414.
57. Yari K., Fatemi S.S.-A., Tavallaei M., Tavallaei M. Optimization of the BoNT/A-Hc expression in recombinant Escherichia coli using the Taguchi statistical method. Biotechnol Appl Biochem 2010, 56:35-42.
58. Woodward L.A., Arimitsu H., Hirst R., Oguma K. Expression of H C subunits from Clostridium botulinum types C and D and their evaluation as candidate vaccine antigens in mice. Infection Immnunity 2003, 71:2941-2944.
59. Baldwin M.R., Tepp W.H., Pier C.L., Bradshaw M., Ho M., Wilson B.A., et al. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect Immun 2005, 73:6998-7005.
60. Baldwin M.R., Tepp W.H., Przedpelski A., Pier C.L., Bradshaw M., Johnson E.A., et al. Subunit vaccine against the seven serotypes of botulism. Infect Immun 2008, 76:1314-1318.
61. Fahnert B., Lilie H., Neubauer P. Inclusion bodies: formation and utilisation. Physiol Stress Responses 2004, 89:93-142.
62. Jensen M.J., Smith T.J., Ahmed S.A., Smith L.A. Expression, purification, and efficacy of the type A botulinum neurotoxin catalytic domain fused to two translocation domain variants. Toxicon 2003, 41:691-701.
63. Frey J., Eberle S., Stahl C., Mazuet C., Popoff M., Schatzmann E., et al. Alternative vaccination against equine botulism (BoNT/C). Equine Vet J 2007, 39:516-520.
64. Sharma S., Zhou Y., Singh B.R. Cloning, expression, and purification of C-terminal quarter of the heavy chain of botulinum neurotoxin type A. Protein Expr Purif 2006, 45:288-295.
65. Tsukamoto K., Kohda T., Mukamoto M., Takeuchi K., Ihara H., Saito M., et al. Binding of Clostridium botulinum type C and D neurotoxins to ganglioside and phospholipid. Novel insights into the receptor for clostridial neurotoxins. JBiol Chem 2005, 280:35164-35171.
66. Chen R., Shi J., Cai K., Tu W., Hou X., Liu H., et al. Improved soluble expression and characterization of the Hc domain of Clostridium botulinum neurotoxin serotype A in Escherichia coli by using a PCR-synthesized gene and a Trx co-expression strain. Protein Expr Purif 2010, 71:79-84.
67. Mansour A.A., Mousavi S.L., Rasooli I., Nazarian S., Amani J., Farhadi N. Cloning, high level expression and immunogenicity of 1163-1256 residues of C-terminal heavy chain of C. botulinum neurotoxin type E. Biologicals 2010, 38:260-264.
68. Zhou Y., Singh B.R. Cloning, high-level expression, single-step purification, and binding activity of His6-tagged recombinant type B botulinum neurotoxin heavy chain transmembrane and binding domain. Protein Expr Purif 2004, 34:8-16.
69. Gilsdorf J., Gul N., Smith L.A. Expression, purification, and characterization of Clostridium botulinum type B light chain. Protein Expr Purif 2006, 46:256-267.
70. Shone C., Agostini H., Clancy J., Gu M., Yang H.-H., Chu Y., et al. Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes. Infect Immun 2009, 77:2795-2801.
71. Przedpelski A., Tepp W.H., Kroken A.R., Fu Z., Kim J.-J.P., Johnson E.A., et al. Enhancing the protective immune response against botulism. Infect Immun 2013, 81:2638-2644.
72. Romanos M.A., Makoff A.J., Fairweather N.F., Beesley K.M., Slater D.E., Rayment F.B., et al. Expression of tetanus toxin fragment C in yeast: gene synthesis is required to eliminate fortuitous polyadenylation sites in AT-rich DNA. Nucleic Acids Res 1991, 19:1461-1467.
73. Byrne M.P., Titball R.W., Holley J., Smith L.A. Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris. Protein Expr Purif 2000, 18:327-337.
74. Dux M.P., Huang J., Barent R., Inan M., Swanson S.T., Sinha J., et al. Purification of a recombinant heavy chain fragment C vaccine candidate against botulinum serotype C neurotoxin [rBoNTC(H(c))] expressed in Pichia pastoris. Protein Expr Purif 2011, 75:177-185.
75. Johnson S.K., Zhang W., Smith L.A., Hywood-Potter K.J., Todd Swanson S., Schlegel V.L., et al. Scale-up of the fermentation and purification of the recombinant heavy chain fragment C of botulinum neurotoxin serotype F, expressed in Pichia pastoris. Protein Expr Purif 2003, 32:1-9.
76. Maddaloni M., Staats H.F., Hoyt T., Robinson A., Callis G., Kozaki S., et al. Mucosal vaccine targeting improves onset of mucosal and systemic immunity to botulinum neurotoxin A. JImmunol 2006, 177:5524-5532.
77. Staats H.F., Fielhauer J.R., Thompson A.L., Tripp A.A., Sobel A.E., Maddaloni M., et al. Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits. PLoS One 2011, 6:e16532.
78. Webb R.P., Smith T.J., Wright P.M., Montgomery V.A., Meagher M.M., Smith L.A. Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins. Vaccine 2007, 25:4273-4282.
79. Webb R.P., Smith T.J., Wright P., Brown J., Smith L.A. Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3. Vaccine 2009, 27:4490-4497.
80. De Angioletti M., Lacerra G., Sabato V., Carestia C. Beta+45 G --> C: a novel silent beta-thalassaemia mutation, the first in the Kozak sequence. Br J Haematol 2004, 124:224-231.
81. Byrne M.P., Smith T.J., Montgomery V.A., Smith L.A. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun 1998, 66:4817-4822.
82. Potter K.J., Bevins M.A., Vassilieva E.V., Chiruvolu V.R., Smith T., Smith L.A., et al. Production and purification of the heavy-chain fragment C of botulinum neurotoxin, serotype B, expressed in the methylotrophic yeast Pichia pastoris. Protein Expr Purif 1998, 13:357-365.
83. Couderc R., Baratti J. Immobilized yeast cells with methanol oxidase activity: preparation and enzymatic properties. Biotechnol Bioeng 1980, 22:1155-1173.
84. Gil L.A.F., CEP da Cunha, Moreira G.M.S.G., Salvarani F.M., Assis R.A., Lobato F.C.F., et al. Production and evaluation of a recombinant chimeric vaccine against Clostridium botulinum neurotoxin types C and D. PLoS One 2013, 8:e69692.
85. Sinha J., Inan M., Fanders S., Taoka S., Gouthro M., Swanson T., et al. Cell bank characterization and fermentation optimization for production of recombinant heavy chain C-terminal fragment of botulinum neurotoxin serotype E (rBoNTE(H(c)): antigen E) by Pichia pastoris. JBiotechnol 2007, 127:462-474.
86. Gurkan C., Ellar D.J. Recombinant production of bacterial toxins and their derivatives in the methylotrophic yeast Pichia pastoris. Microb Cell Fact 2005, 4.
87. Krainer F.W., Dietzsch C., Hajek T., Herwig C., Spadiut O., Glieder A. Recombinant protein expression in Pichia pastoris strains with an engineered methanol utilization pathway. Microb Cell Fact 2012, 11.
88. Lee J.S., Pushko P., Parker M.D., Dertzbaugh M.T., Smith L.A., Smith J.F. Candidate vaccine against botulinum neurotoxin serotype a derived from a venezuelan equine encephalitis virus vector system. Infect Immun 2001, 69:5709-5715.
89. Yu Y., Yu J., Li N., Wang S., Yu W., Sun Z. Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based semliki forest virus vectors. Vaccine 2009, 27:6148-6153.
90. Zichel R., Mimran A., Keren A., Barnea A., Steinberger-Levy I., Marcus D., et al. Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system. Clin Vaccine Immunol 2010, 17:784-792.